A 68-week trial published in the New England Journal of Medicine showed that participants taking semaglutide lost an average of 14% of their body weight, compared to a 3% loss in the placebo group
Paradoxically, many patients report feeling more energetic after the first month because reduced joint pain, better sleep quality, and decreased inflammation from weight loss outweigh the small metabolic dip
However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo
How PlexusDx Supports a More Personalized Approach For adolescents with severe obesity and metabolic complications, genetic insights into appetite-regulation pathways may help provide context for underlying predispositions
Zhu YH, Qin C, Sun, et al
